Initiating oral fingolimod treatment in patients with multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 6, Issue 4, 2013, Pages 269-275

  Singer, Barry A ^a  

^a MISSOURI BAPTIST MEDICAL CENTER   (United States)

Author keywords

fingolimod; multiple sclerosis; patient selection; risk; safety

Indexed keywords

AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; ATROPINE; BETA1A INTERFERON; BILIRUBIN; FINGOLIMOD; GLATIRAMER; ISOPRENALINE; NATALIZUMAB; PLACEBO; STEROID;

AMINOTRANSFERASE BLOOD LEVEL; AORTOPULMONARY SEPTAL DEFECT; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DISEASE COURSE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY MONITORING; EUROPEAN UNION; FIRST DEGREE ATRIOVENTRICULAR BLOCK; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HEART VENTRICLE SEPTUM DEFECT; HERPES ZOSTER; HERPES ZOSTER ENCEPHALITIS; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INFECTION; INJECTION SITE NECROSIS; INJECTION SITE REACTION; LIPOATROPHY; MULTIPLE SCLEROSIS; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOLOGY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PRIORITY JOURNAL; PULSE RATE; RECURRENCE RISK; RELAPSE; REVIEW; RISK ASSESSMENT; SECOND DEGREE ATRIOVENTRICULAR BLOCK; TELEMETRY; TERATOGENICITY; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

EID: 84880391860     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285613491520     Document Type: Article

References (28)

1. Afshar A. Fernandes J. Patel R. Ksiazek S. Sheth V. Reder A. et al. (2013) Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol 131: 103–107.
2. Bloomgren G. Richman S. Hotermans C. Subramanyam M. Goelz S. Natarajan A. et al. (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366: 1870–1880.
3. Calabresi P. Goodin D. Jeffery D. Kappos L. Lublin F. Rammohan K. et al. (2012) Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing-remitting multiple sclerosis. Presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 10–13 October 2012, Lyon, France. [abstract P491].
4. Centonze D. Rossi S. Rinaldi F. Gallo P. (2012) Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 79: 2004–2005.
5. Chun J. Brinkmann V. (2011) A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 12: 213–228.
6. Chun J. Hartung H. (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33: 91–101.
7. Cohen J. Barkhof F. Comi G. Hartung H. Khatri B. Montalban X. et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402–415.
8. Di Marco J. O'Connor P. Cohen J. Reder A. Zhang-Auberson L. Tang D. et al. (2012) Fingolimod treatment initiation experience: cardiac and Holter electrocardiogram findings from three phase 3 studies. Presented at of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 10–13 October 2012, Lyon, France [abstract P530].
9. European Medicines Agency. (2012). Available at: http://www.ema.europa.eu/ema/ (accessed 27 November 2012).
10. Foster C. Howard L. Schweitzer A. Persohn E. Hiestand P. Balatoni B. et al. (2007) Brain penetration of the oral immunomodulatory drug FTY 720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323: 469–475.
11. Francis G. Kappos L. O'Connor P. Collins W. Zhang-Auberson L. de Vera A. et al. (2010) Lymphocytes and fingolimod - temporal pattern and relationship with infections. Presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 13–16 October 2010, Gothenburg, Sweden [abstract P442].
12. Gasperini C. Ruggieri S. (2012) Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach. Drug Des Dev Ther 6: 175–186.
13. Gilenya® (fingolimod). (2012). Full Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
14. Gross C. Baumgartner A. Rauer S. Stich O. (2012) Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology 79: 2006–2007.
15. Jain N. Bhatti T. (2012) Macular edema associated with fingolimod. EyeNet April: 43–45.
16. Kappos L. Radue E. O'Connor P. Polman C. Hohlfeld R. Calabresi P. et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387–401.
17. Katial R. Ratto-Kim S. Sitz K. Moriarity R. Engler R. (1999) Varicella immunity: persistent serologic non-response to immunization. Ann Allergy Asthma Immunol 82: 431–434.
18. Mikol D. Barkhof F. Chang P. Coyle P. Jeffery D. Schwid S. et al. (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7: 903–914.
19. Novartis (2012) PrGILENYA*, Fingolimod (as fingolimod hydrochloride). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.
20. O'Connor P. Filippi M. Arnason B. Comi G. Cook S. Goodin D. et al. (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8: 889–897.
21. Prosperini L. Gallo V. Petsas N. Borriello G. Pozzilli C. (2009) One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 16: 1202–1209.
22. Ratchford J. Costello K. Reich D. Calabresi P. (2012) Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology 79: 2002–2004.
23. Rio J. Castillo J. Rovira A. Tintore M. Sastre-Garriga J. Horga A. et al. (2009) Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 15: 848–853.
24. Rio J. Rovira A. Tintore M. Huerga E. Nos C. Tellez N. et al. (2008) Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 14: 479–484.
25. Rio J. Tintore M. Sastre-Garriga J. Nos C. Castillo J. Tur C. et al. (2012) Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol 19: 899-904.
26. Sanna M. Liao J. Jo E. Alfonso C. Ahn M. Peterson M. et al. (2004) Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279: 13839–13848.
27. Turner A. Williams R. Sloan A. Haselkorn J. (2009) Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Rehabil Psychol 54: 116–121.
28. Visser F. Wattjes M. Pouwels P. Linssen W. van Oosten B. (2012) Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 79: 2000–2003.